ClinicalTrials.gg
CompletedNCT03942458Updated Sep 19, 2019

Pharmacokinetics and Pharmacodynamics of Vicagrel in Healthy Adult Subjects of Different CYP2C19

A Phase 1 interventional study of Vicagrel 6mg and Clopidogrel 75mg in Healthy Subjects and PK/PD, sponsored by Jiangsu vcare pharmaceutical technology co., LTD. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-19.

Sponsored by Jiangsu vcare pharmaceutical technology co., LTD · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a single-center, randomized, open, two-cycle crossover, clopidogrel control, multiple dosing study. The aim was to evaluate the pharmacokinetic/pharmacodynamic behavior of different metabolites of CYP2C19 in healthy subjects. The study enrolled 48 patients, divided into three groups of CYP2C19 fast metabolite, middle metabolite, and slow metabolism, 16 cases in each group. All groups of subjects were administered for 7 days in the first cycle, once a day (loading dose on the first day, maintenance dose on other days), and entering the 14-day washout period after the end of the first cycle. The second cycle was entered, and the second cycle was administered for 7 days, once a day (the first day was given a loading dose, and the other days were given a maintenance dose). Blood was collected before and after administration of D1, D7, D22, and D28, and PK/PD was measured.

02

Conditions studied

  • Healthy Subjects
  • PK/PD
03

In context

Lead sponsor

Jiangsu vcare pharmaceutical technology co., LTD is the lead sponsor of 35 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary signing of before the trial, and full understanding of the experimental content, process and possible adverse reactions;
  • Subjects with ability and adherence to trial protocol;
  • Subjects (including partners) voluntarily take effective measures from screening to the last study drug administration within 6 months;
  • Male and female aged 18-45,gender is unlimited (including 18 and 45 years old);
  • Male Weight ≥50 kg, female Weight ≥ 45 kg, and ranging from 18 to 28 kg/m2 (including critical values);
  • Physical examination, normal or abnormal vital signs have no clinical significance (reference range of vital signs: systolic blood pressure 90-150 mmHg, diastolic blood pressure 50-95 mmHg, pulse 50-110 beats/min, body temperature 35.5-37.2 °C);
  • CYP2C19 rapid metabolizers (CYP2C19*1/*1), or intermediate metabolizers (CYP2C19*1/*2, CYP2C19*1/*3), or poor metabolizers (CYP2C19*2/*2, CYP2C19*2/* 3, CYP2C19*3/*3).

Exclusion criteria

Exclusion Criteria:

  • More than 5 cigarettes per day 3 months before the trial;
  • History of allergies or allergies to the drug (two or more drugs or food allergies);
  • History of drug and/or alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);
  • Donate blood or massive blood loss (> 450 mL) within 3 months prior to formal screening;
  • Take any drug that alters the activity of CYP450s within 28 days before the formal screening;
  • Take any prescription, non-prescription, any vitamin or herbal medicine within 14 days of the formal screening;
  • Take special diet (including dragon fruit, mango, grapefruit, etc.) within 2 weeks before the formal screening, or have strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, excretion, etc.;
  • Taking inhibitors or inducers of the , P-gp or Bcrp Currently, such as itraconazole, ketoconazole or dronedarone;
  • Recently there have been major changes in diet or exercise habits;
  • Taking other research drugs or participating in clinical trials within 3 months before taking the study drug;
  • History of dysphagia or any gastrointestinal disease affecting drug absorption;
  • Have any disease that increases the risk of bleeding, such as acute gastritis, stomach and duodenal ulcers, thrombocytopenic purpura, hemophilia, and so on;
  • abnormalities have clinical significance;
  • Female subjects are in lactation or have a positive of pregnancy test;
  • Clinical laboratory abnormalities have clinical significance or other abnormalities (including but not limited to gastrointestinal, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases);
  • Infectious diseases (two pairs of , antibodies, , Treponema pallidum antibodies) have positive results;
  • Acute disease or concomitant medication from the screening to the study;
  • Taking chocolate, any food or drink with caffeine or jaundice-rich within 48 hours before taking the study drug;
  • Any alcoholic product or alcohol breath test positive within 24 hours before taking the study drug;
  • Urine drug test (morphine, marijuana) is positive;
  • The investigator believes that there are other factors who are not suitable for participating in the test.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Vicagrel

    Vicagrel 24mg loading followed by 6mg/day for 6 days

    Drug: Vicagrel 6mg

  • Active comparator
    Clopidogrel

    Clopidogrel 300mg loading followed by 75mg/day for 6 days

    Drug: Clopidogrel 75mg

Interventions

  • Vicagrel 24mg loading followed by 6mg/day for 6 days

  • Clopidogrel 300mg loading followed by 75mg/day for 6 days

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax)

    To evaluate the Peak Plasma Concentration (Cmax) after taking drugs

    Time frame: 1 day,7 days after taking drugs

  2. Area under the plasma concentration versus time curve (AUC)

    To evaluate the AUC after taking drugsl

    Time frame: 1 day,7 days after taking drugs

  3. Time to maximum plasma concentration (Tmax)

    To evaluate the Tmax after taking drugs

    Time frame: 1 day,7 days after taking drugs

  4. terminal half-life (T1/2)

    To evaluate the T1/2 after taking drugs

    Time frame: 1 day,7 days after taking drugs

  5. inhibition of platelet aggregation

    To evluate the inhibition of platelet aggregation assessed by Verifynow System after taking drugs

    Time frame: 1 day,7 days after taking drugs

07

Study locations

1 site
  • The First Hospital of Jilin University
    Chang chun, Jilin 130021, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2019
First posted
May 8, 2019
StartActual
Apr 3, 2019
Primary completionActual
Jun 28, 2019
CompletionActual
Sep 3, 2019
Last update
Sep 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03942458
Responsible party
Sponsor
First posted
May 8, 2019
Start date
Apr 3, 2019
Primary completion
Jun 28, 2019
Completion
Sep 3, 2019
Last update
Sep 19, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sumecigrel

Start the discussion